AI in Healthcare

Today's Stories

1. 1

   Bristol Myers Squibb Partners with Chai Discovery to Use AI for Antibody Design

   Bristol Myers Squibb announced a strategic collaboration with Chai Discovery, a 2024-founded AI company, to integrate Chai's molecular folding and de novo design models into BMS's drug discovery process for therapeutic antibodies. Instead of relying on traditional lab-based screening that can take 12 to 24 months, Chai's platform uses AI to design antibodies from scratch in weeks, potentially unlocking discovery of difficult-to-target disease mechanisms. This represents a shift in the biopharma industry toward AI-driven discovery; Chai has also partnered with Eli Lilly, Pfizer, and Novartis.

   The integration will create a continuously learning discovery system within BMS's portfolio. Chai was founded in 2024 by Joshua Meier (CEO), Jack Dent (President), Matthew McPartlon (CTO), and Jacques Boitreaud, drawing talent from OpenAI, Meta FAIR, Stripe, and Absci.

2. 2

   Bristol Myers Squibb partners with AI firm Chai for antibody drug discovery

   Bristol Myers Squibb (BMS) has partnered with Chai Discovery, an AI company, to use artificial intelligence for discovering therapeutic antibodies. BMS will access Chai's AI models, including molecular folding and design capabilities, to identify antibody candidates across its drug portfolio. AI is accelerating early-stage drug discovery by compressing development cycles and enabling scientists to target candidates that traditional methods have historically struggled to reach. This collaboration signals that major pharmaceutical companies are rapidly adopting AI platforms to build what BMS calls an 'AI-powered, continuously learning discovery system.' For pharmaceutical and biotech firms, the adoption of such tools may enable faster progression from concept to viable therapeutic candidates.

   BMS is the latest major pharma partner for Chai Discovery; Pfizer entered a license agreement with Chai Discovery in June to accelerate drug discovery research.

3. 3

   Tempus AI Jumps on Merck-Moderna Cancer Trial Win

   Tempus AI's stock surged following a Merck and Moderna cancer trial that demonstrated positive results using Personalis technology, which Tempus acquired. The trial outcome validated the company's investment in the Personalis acquisition. The successful cancer trial provides real-world evidence that Tempus's acquisition of Personalis—a genomics and diagnostics company—can deliver clinical value in oncology, strengthening Tempus's position in precision medicine and potentially opening pathways for broader adoption in cancer treatment.

   The results may accelerate Tempus's ability to commercialize Personalis's genomic capabilities in partnership with major pharmaceutical and biotech players like Merck and Moderna.

4. 4

   Mayo Clinic appoints new CIO from Honeywell to lead AI expansion

   Mayo Clinic appointed Arun Kumar Bhaskara-Baba as chief information officer in May, succeeding Cris Ross who retired in 2024 after 12 years. Bhaskara-Baba joins from Honeywell Aerospace and Defense, where he directed digital strategy and scaled the company's artificial intelligence capabilities. Bhaskara-Baba brings more than 25 years of tech experience, including work at Johnson & Johnson and Dell in IT leadership roles spanning manufacturing, risk management, quality, compliance, and information security. His background scaling AI capabilities positions him to lead Mayo's expansion of AI systems across its network of 16 hospitals and 45 multispecialty clinics.

   Mayo is doubling down on AI infrastructure — in June the health system announced a partnership with Microsoft to build a "frontier" AI model for earlier diagnosis and treatment planning, and deployed advanced AI infrastructure created by NVIDIA for drug discovery.

5. 5

   Aily Labs Brings AI Decision Platform to Google Cloud Marketplace for Pharma

   Aily Labs, an AI Decision Intelligence platform company, partnered with Google Cloud to make its platform available on the Google Cloud Marketplace. The move lets pharmaceutical and biotech firms buy Aily's AI agents directly through existing Google Cloud contracts, and those purchases count toward their committed cloud spend without triggering separate vendor reviews or new security evaluations. Pharma and biotech companies typically juggle R&D, clinical trials, regulatory compliance, and supply chains across dozens of disconnected systems—delays in trial site selection, drug candidate prioritization, and inventory decisions often result. By offering Aily's platform through Google Cloud, enterprises can tap AI agents for drug development and regulatory work without extra procurement friction or security audits.

   Aily's "Super Agent" orchestrates thousands of specialized AI sub-agents across R&D, clinical development, regulatory filings, capital allocation, supply chain, and commercial operations—all accessible via the Agent Gallery within Gemini Enterprise, Google Cloud's enterprise AI application.

6. 6

   Protein design market seen reaching $15.71B by 2030 on AI push

   The global protein design and engineering market is projected to grow from $7.62 billion in 2025 to $8.79 billion in 2026, a compound annual growth rate of 15.4%, and reach $15.71 billion by 2030 at a CAGR of 15.6% between 2026 and 2030. AI-powered drug discovery, synthetic biology adoption, and rising investment in precision medicine are reshaping how pharmaceutical companies develop biologics and vaccines. Protein engineering improves the stability, efficacy, manufacturability and target specificity of therapeutic proteins, making it central to the next wave of drug development.

   Key growth drivers include AI-driven protein structure prediction, computational modeling for novel enzyme design, de novo protein engineering for therapeutics, and integration of high-throughput screening into protein optimization workflows. Asia-Pacific is flagged as offering expansion potential.